Roche Diabetes Care at the virtual EASD 2020 meeting

September 21 – 25, 2020, extended to October 23, 2020

Order Publications and Solution Brochures

Exhibit Info

Exhibit Info

We look forward to welcoming you to the virtual Roche Diabetes Care exhibition booth! Take a walk across our virtual booth and find out more on integrated personalised diabetes management. Feel free to chat with our booth personnel or contact us for further information.

Conference Location:

Virtual Meeting

Exhibition:

Hall London

booth number L.01

Opening hours:

Monday - Thursday: 9:00 - 17:00

Friday: 9:00 - 15:00

Roche Diabetes Care Symposium

Personalising the management of diabetes and its complications

Monday, September 21, 2020
Time: 12.30 – 14.00 h CET

Salzburg Hall

Chairs: Antonio Ceriello (Italy), Rolf Hinzmann (Roche Diabetes Care, Germany)

Speaker

integrated Personalised Diabetes Management (iPDM): Diabetes outcomes through an open ecosystem

Jörg Hölzing

Roche Diabetes Care

Basel, Switzerland

Clinical evidence shows: Micropumps demonstrate new opportunities to optimise insulin pump therapy

Nick Oliver

Imperial College London

London, UK

Personalised cardiovascular risk management: Pivotal in preventing complications in people with diabetes

James Januzzi

Massachusetts General Hospital & Harvard Medical School

Boston, MA, USA

Abstracts & Posters

First results from PRO Solo: patient reported outcomes from a clinical trial comparing a new patch pump with MDI and an established patch pump

First results from PRO Solo: patient reported outcomes from a clinical trial comparing a new patch pump with MDI and an established patch pump

  • PS 61 Insulin pump therapy – Poster Hall - 22. September 2020, 12:00 - 13:00 h
  • Author: Julia Mader et al.

Mobile health application usage shows long-term improvement on blood glucose control

Mobile health application usage shows long-term improvement on blood glucose control

  • OP 18 Unlocking the potential of digital health – Klagenfurt Hall - 23. September 2020, 10:15 - 10:30 h
  • Author: Valerie Eichinger et al.

Epidemiology and treatment of chronic kidney disease among commercially-insured patients in the US

Epidemiology and treatment of chronic kidney disease among commercially-insured patients in the US

  • PS 04 Global view on diabetes complications – Poster Hall - 23. September 2020, 13:15 - 14:15 h
  • Author: Teresa Kauf et al.

Receive Roche Diabetes Care solutions brochures and publications links via email!

Order now

Publications:

Use of an Insulin Bolus Advisor Improves Glycemic Control in Multiple Daily Insulin Injection (MDI) Therapy Patients With Suboptimal Glycemic Control: First results from the ABACUS trial
(Ziegler et al. Diabetes Care. 2013 Nov;36(11):3613-9.)
Use of an Automated Bolus Calculator in MDI-Treated Type 1 Diabetes - The BolusCal Study, a randomized controlled pilot study
(Schmidt et al. Diabetes Care. 2012 May;35(5):984-90.)
System Accuracy Evaluation of 43 Blood Glucose Monitoring Systems for Self-Monitoring of Blood Glucose According to DIN EN ISO 15197
(Freckmann et al. J Diabetes Sci Technol. 2012 Sep 1;6(5):1060-75.)
Use of a Novel, Remotely Connected Diabetes Management System Is Associated with Increased Treatment Satisfaction, Reduced Diabetes Distress, and Improved Glycemic Control in Individuals with Insulin-Treated Diabetes: First Results from the Personal Diabetes Management Study
(Mora et al. Diabetes Technol Ther. 2017 Dec 1; 19(12): 715–22.)
Evaluation of a new digital automated glycemic pattern detection tool
(Comellas et al. Diabetes Technol Ther. 2017 Nov 1; 19(11): 633–40.)
Use of Diabetes Data Management Software Reports by Health Care Providers, Patients With Diabetes, and Caregivers Improves Accuracy and Efficiency of Data Analysis and Interpretation Compared With Traditional Logbook Data: First Results of the Accu-Chek Connect Reports Utility and Efficiency Study (ACCRUES)
(Hinnen et al. J Diabetes Sci Technol. 2015 Mar;9(2):293-301.)
What Do We Need beyond Hemoglobin A1c to Get the Complete Picture of glycemia in people with diabetes?
(Hinzmann et al. Int J Med Sci. 2012;9(8):665-81)
A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II
(Christiansen et al. Diabetes Technol Ther. 2018 Jan 30 (Epub))
Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial
(Kropff et al. Diabetes Care. 2017 Jan;40(1):63-68.)
(Heinemann et al. J Diabetes Sci Technol. 2019 Jun [epub])
Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice
(Johnson et al. J Diabetes Sci Technol. 2019 Jun;21(S2):S217-S225.)
Boluses in insulin therapy
(Ziegler et al. J Diabetes Sci Technol 2017; 11(1):165-71.)
Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study
(Steineck et al. BMJ 2015; 350: h3234.)
Open Source Closed-Loop Insulin Delivery Systems: A Clash of Cultures or Merging of Diverse Approaches?
(Barnard et al. J Diabetes Sci Technol. 2018 Nov;12(6):1223-1226)
Patch Pumps: Are They All the Same?
(Heinemann et al. J Diabetes Sci Technol. 2019 Jan;13(1):34-40.)
Establishing methods to determine clinically relevant bolus and basal rate delivery accuracy of insulin pumps
(Kamecke et al. J Diabetes Sci Technol 2018; ePub)
Occlusion detection time in insulin pumps at two different basal rates
(Freckmann et al. J Diabetes Sci Technol 2018 ;12(3):608–613)
Continuous subcutaneous insulin infusion: Special needs for children
(Adolfsson et al. Pediatr Diabetes. 2017 Jun;18(4):255-261)
Using insulin pump with a remote-control system in young patients with diabetes improves glycemic control and enhances patient satisfaction
(Deeb et al. Clin Diabetes Endocrinol. 2019 Jun 6;5:7.)
Accuracy of bolus and basal rate delivery of different insulin pump systems
(Freckmann et al. Diabetes Technol Ther. 2019 Apr;21(4):201-208.)
Comparative handling analysis of different insulin pump systems
(Waldenmaier et al. J Diabetes Sci Technol. 2018 Mar; 12(2): 401–406.)
Concept and implementation of a novel patch pump for insulin delivery
(Ulbrich et al. J Diabetes Sci Technol. 2019 Aug [epub])
Utilizing eHealth and telemedicine technologies to enhance access and quality
(Barnard et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
A digital-first model of diabetes care
(Cafazzo et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Real-world assessments of mySugr mobile health app
(Debong et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Use of artificial intelligence to improve diabetes outcomes in patients using multiple daily injections therapy
(Forlenza et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
The emerging role of telemedicine and mobile health technologies in improving diabetes care
(Garg et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Current status and future directions for electronic point-of-care clinical decision support
(O’Connor et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Use of telemedicine technologies in diabetes prevention and control in resource-constrained settings - lessons learned from emerging economies
(Pradeepa et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Virtual coaching to enhance diabetes care
(Ramchandani et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Benefit of digital tools used for Integrated Personalized Diabetes Management: results from the PDM-ProValue Study Program.
(Heinemann et al. J Diabetes Sci Technol. 2019 Aug [epub])
Patient-centred care in type 2 diabetes mellitus - key aspects of PDM-ProValue are reflected in the 2018 ADA/EASD consensus report.
(Fritzen et al. Diabetes Res Clin Pract. 2019 Dec [epub])
Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program
(Kulzer et al. Diab Res Clin Pract. 2018 Oct;144:200-212)
Integrated Personalized Diabetes Management (PDM): Design of the ProValue Studies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabetes.
(Kulzer et al. J Diabetes Sci Technol. 2016 May 3;10(3):772-81.)
PDM-ProValue meets cardiovascular outcome trials in diabetes
(Fritzen et al. Cardiovasc Diabetol. 2019 Jan 28;18(1):10)
Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data
(Ravizza et al. Nat Med. 2019 Jan;25(1):57-59.)
Modeling of Diabetes and Its Clinical Impact
(Fritzen et al. J Diabetes Sci Technol. 2018 Sep;12(5):976-984.)
Continuous intraperitoneal insulin infusion: an alternative route for insulin delivery in type 1 diabetes.
(Pasquini et al. Acta Diabetol. 2019 Aug 9.)
A New Optimized Percutaneous Access System for CIPII
(Garcia-Verdugo et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study.
(Dassau et al. Diabetes Obes Metab. 2017 Dec;19(12):1698-1705.)
New design of a percutaneous port system for continuous intraperitoneal insulin infusion
(Rieger et al. J Diabetes Sci Technol. 2019 Jun [epub])
Overnight closed-loop control improves glycemic control in a multicenter study of adults with type 1 diabetes
(Brown et al. Clin Endocrinol Metab. 2017 Oct 1;102(10):3674-3682.)
Twelve-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin a1c and hypoglycemia.
(Dassau et al. Diabetes Care. 2017 Dec;40(12):1719-1726.)
Closed-loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study.
(Breton et al. Diabetes Care. 2017 Dec;40(12):1644-1650.)
Closed-loop control without meal announcement in type 1 diabetes.
(Cameron et al. Diabetes Technol Ther. 2017 Sep;19(9):527-532.)
Artificial pancreas: clinical study in latin america without premeal insulin boluses.
(Sanchez-Pena et al. J Diabetes Sci Technol. 2018 Sep;12(5):914-925.)
Day-and-night closed-loop control using the unified safety system in adolescents with type 1 diabetes at camp.
(Ly et al. Diabetes Care. 2016 Aug;39(8):e106-7.)
Outpatient closed-loop control with unannounced moderate exercise in adolescents using zone model predictive control
(Huyett et al. Diabetes Technol Ther. 2017 Jun 1; 19(6): 331–339.)

Brochures - Our Solutions:

Accu-Chek® Solo

  • First detachable and tube-free insulin pump
  • Unique quick bolus buttons on pump
  • Diabetes Manager with open bolus advice to combine therapy with continuous glucose monitoring solutions

mySugr

  • Quick, automated, easy-to-understand logging of BG levels, via Bluetooth
  • Automatic data integration of leading BG meters (e.g. Accu-Chek Guide), CGM devices (e.g. Eversense XL), as well as cloud-based integrations (Apple Health, Google Fit); New integrations: BG integration into RocheDiabetes Care Platform, soon NovoPen® 6 and NovoPen Echo® Plus integration
  • mySugr Pro Bolus calculator
  • Comprehensive reports
  • More than 2 million registered users

Accu-Chek® Instant

  • Clean strip disposal – Touchless disposal of strips with the ejector button
  • Easy testing – Patients can touch their blood anywhere along the entire width of the yellow edge.
  • Easy testing – Patients can touch their blood anywhere along the entire width of the yellow edge.
  • Connection to mySugr app – No more manual diaries

RocheDiabetes Care Platform

  • Provides quick insights to identify patterns and trends to support clinical decision making
  • Simple reports facilitate communication to help support patient-learning and engagement
  • Open connectivity to +140 devices to increase patient insights and simplify workflow, including smart insulin pens (Novo Nordisk smart pens)

Remote Patient Monitoring Module of RocheDiabetes Care Platform

  • Integrated diabetes management tool, allowing broad data integration through an open ecosystem
  • Visibility of patient data remotely, allowing the generation of actionable insights to improve quality of care
  • Ability to adjust therapy without patient needing to be physically present, eliminating location boundaries
  • Higher engagement, adherence, and assurance of people with diabetes with their therapy, improving outcomes

RocheDiabetes InsulinStart

  • Guided process that provides clear, actionable advice to the person with diabetes, for a safe and effective start at insulin therapy
  • Proven algorithms help people with diabetes find their optimum insulin dosage
  • Add-on to the Accu-Chek Smart Pix software

Accu-Chek® Guide

  • Easy-to-remove test strips with spill-resistant SmartVial
  • Strip port light, wide, easy-edge test strip, and meter strip ejection
  • Wireless transmission of results to mySugr app

Accu-Chek® Smart Pix

  • Open version allows for read-out of devices from Roche and other manufacturers
  • All data seamlessly available in one system
  • Easy and fast conclusions and therapy adaptations possible
  • Easily understandable visualization of different diabetes-relevant data

Accu-Chek® Insight

  • Intuitive & discreet: Diabetes manager with full remote control with bolus advice, and accurate insulin delivery
  • Easy & safe: Pre-filled cartridge, no air bubbles to remove, sensitive occlusion detection

Eversense XL

  • Up to 6 months wearing time
  • Removable smart transmitter with on-body vibe alerts
  • Predictive alerts before reaching low or high glucose levels
  • Simple, 5-minute in-office insertion
  • Wireless data connection to mySugr

Accu-Chek® SugarView

  • All you need is a smartphone, an Accu-Chek Active blood glucose test strip, a lancet, and the app to see your blood glucose test range and know what to do next.
  • Feel motivated and assured about your type 2 diabetes as you know your next step.
  • Know how you are doing in between your doctor’s appointments in an affordable way.

mySugr Bundle

Available in the U.S. and Germany, the mySugr Bundle is our all-in-one solution for people with diabetes delivered right to the doorstep to support daily therapy management